001027704 001__ 1027704
001027704 005__ 20240626202012.0
001027704 0247_ $$2doi$$a10.1055/s-0042-1746012
001027704 037__ $$aFZJ-2024-04014
001027704 041__ $$aGerman
001027704 1001_ $$0P:(DE-Juel1)131679$$aElmenhorst, D.$$b0$$eCorresponding author$$ufzj
001027704 1112_ $$a60. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin$$cLeipzig$$d2022-04-27 - 2022-04-30$$wGermany
001027704 245__ $$aA1 adenosine receptor occupancy and availability after 5-day regular coffee consumption and subsequent abstention
001027704 260__ $$c2022
001027704 3367_ $$033$$2EndNote$$aConference Paper
001027704 3367_ $$2DataCite$$aOther
001027704 3367_ $$2BibTeX$$aINPROCEEDINGS
001027704 3367_ $$2DRIVER$$aconferenceObject
001027704 3367_ $$2ORCID$$aLECTURE_SPEECH
001027704 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1719375474_17755$$xAfter Call
001027704 520__ $$aZiel/Aim The stimulating effects of commonly consumed caffeine, the majorpsychostimulant ingredient of coffee, are evoked through non-selective antagonismat adenosine receptors. [F-18]CPFPX is a highly selective and affine ligandat the A1 adenosine receptor (A1AR) and has been successfully implementedas PET ligand. Here, we quantified by [F-18]CPFPX PET the in vivo brainoccupancy of A1AR after short-term coffee consumption during sleep restrictionand subsequent abstinence in the human brain.Methodik/Methods Nine healthy volunteers (29 ± 5 years, 4f/5m) completedan 8-day in-lab study including 3 x 110-min bolus plus constant infusion [F-18]CPFPX PET experiments. After a baseline PET scan in the afternoon following 2weeks of caffeine abstinence, participants consumed freshly brewed coffee for5 consecutive days, while time in bed was restricted to 5 h per night. The administeredcoffee contained 200 mg caffeine at 7:30 h and 100 mg caffeine at14:00 h. Subsequent PET scans were conducted at the same time of day as inbaseline, roughly 7 h after final coffee intake in the morning and after ~ 31 hof coffee abstention including an 8h-sleep episode. Metabolite corrected bloodsamples were used to calculate steady-state distribution volumes (VT) (i.e.,50-100 min after start of [F-18]CPFPX administration). Caffeine levels in salivawere determined regularly. Occupancy levels were calculated by applying theLassen plot including cortical and subcortical areas, cerebellum and pons.Ergebnisse/Results Dependent on the resulting plasma concentrations ofcaffeine, [F-18]CPFPX binding was reduced between 7 and 38 %. The caffeinedoseto A1AR-occupancy relation was comparable to the previously estimatedrelation with an IC50 of 67 μM in plasma corresponding to 460 mg caffeine per70 kg subject (approximately 4.5 cups of coffee). One day after coffee abstention,VT values did not differ from baseline.Schlussfolgerungen/Conclusions Our preliminary data suggest that the consumptionof 3 cups of coffee for 5 days does not alter A1AR brain availabilityafter 24h hours of caffeine abstention.
001027704 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001027704 588__ $$aDataset connected to CrossRef Conference
001027704 7001_ $$0P:(DE-HGF)0$$aElmenhorst, E.$$b1
001027704 7001_ $$0P:(DE-Juel1)165827$$aLange, D.$$b2
001027704 7001_ $$0P:(DE-HGF)0$$aBaur, D.$$b3
001027704 7001_ $$0P:(DE-Juel1)133864$$aBeer, Simone$$b4$$ufzj
001027704 7001_ $$0P:(DE-Juel1)179271$$aPierling, A.$$b5$$ufzj
001027704 7001_ $$0P:(DE-Juel1)131691$$aKroll, T.$$b6$$ufzj
001027704 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, B.$$b7$$ufzj
001027704 7001_ $$0P:(DE-HGF)0$$aAeschbach, D.$$b8
001027704 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b9$$ufzj
001027704 7001_ $$0P:(DE-HGF)0$$aLandolt, H.$$b10
001027704 773__ $$a10.1055/s-0042-1746012
001027704 909CO $$ooai:juser.fz-juelich.de:1027704$$pVDB
001027704 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich$$b0$$kFZJ
001027704 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133864$$aForschungszentrum Jülich$$b4$$kFZJ
001027704 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)179271$$aForschungszentrum Jülich$$b5$$kFZJ
001027704 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich$$b6$$kFZJ
001027704 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b7$$kFZJ
001027704 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b9$$kFZJ
001027704 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001027704 920__ $$lyes
001027704 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001027704 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
001027704 980__ $$aconf
001027704 980__ $$aVDB
001027704 980__ $$aI:(DE-Juel1)INM-5-20090406
001027704 980__ $$aI:(DE-Juel1)INM-2-20090406
001027704 980__ $$aUNRESTRICTED